Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2020

View Archived Issues

Sosei Heptares identifies antiviral small molecules for COVID-19

iSD and Biogen establish strategic research collaboration for ISD-017 for SLE

Further positive data from phase II study of GV-1001 in Alzheimer's disease

Positive topline data from phase IIb study of ARQ-154 in scalp and body psoriasis

Ascentage receives approval for phase Ib/II studies of APG-2575 in China

Onconova files IND application with FDA for ON-123300

Positive topline data from phase II OLE study of Tesomet in hypothalamic obesity

Chinese researchers patent compounds for liver diseases

ViiV Healthcare divulges new HIV1 inhibitors

AiCuris synthesizes HBV capsid assembly inhibitors

European researchers discover new NR1I3 agonists

New antibodies for COVID-19 presented by University of Pittsburgh

OBI Pharma provides promising phase I data for OBI-833

Phase II data presented for saroglitazar in patients with PBC

BCL6 degrader works via combine and conquer strategy

Targovax reports 18-month data from phase I/II study of ONCOS-102 in mesothelioma

Late events dog gene therapy

Bad seeds get an early start in AD

Phase II interim analysis of HER-Vaxx in advanced gastric cancer shows improved OS

Treatment begins in phase II/III study of Evgen's SFX-01 for ARDS

KN-046 plus KN-026 in HER2-positive solid tumors well tolerated, shows antitumoral activity

FDA approves Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies

First cohort data from phase I study of GRAd-COV2 show immune responses

Phase I/II study of SBI-101 for severe COVID-19 begins dosing

Clazosentan reduces all-cause morbidity and mortality post-aSAH in Japanese registration trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...